唑来膦酸在一例多发性骨髓瘤患者中的应用_West China Medical Journal

Authors：

游泽莉 ¹ ,  陈德才 ²

Corresponding author：

陈德才, Email: 502254056@qq.com

Keywords：

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 游泽莉,陈德才. 唑来膦酸在一例多发性骨髓瘤患者中的应用. West China Medical Journal, 2011, 26(7): 1119-. doi: Copy

1.	Zeimer H, Firkin F, Grill V, et al. A ssessm en t of cellular expression of parathyroid hormone-related protein mRNA and protein in multiple myeloma[J]. J Pathol, 2000, 192(3): 336-341.
2.	Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials[J]. J Clin Oncol, 2001, 19(2): 558-567.
3.	Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases inpatients with breast cancer or osteolytic lesions of multiple myeloma: a phaseⅢ, double-blind, comparative trial [J].Cancer J, 2001, 7(5): 377-387.
4.	Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial[J]. Cancer, 2003, 98(8): 1735-1744.
5.	罗利琼, 张丽娟, 冯刚. 唑来膦酸治疗多发性骨髓瘤骨痛的疗效[J]. 实用医学杂志, 2010, 26(17): 3223-3224.
6.	Santini D, Fratto ME, Vincenzi B, et al. Bisphosphonate effects in cancer and inflammatory diseases: in vitro and in vivo modulation of cytokine activities[J]. BioDrugs, 2004, 18(4): 269-278.
7.	Heidenreich A, Ohlmann CH. Ibandronate its pharmacology and clinical efficacy in the management of tumor-induced hypercalcemia and metastatic bone disease[J]. Expert Rev Anticancer Ther, 2004, 4(6): 991-1005.
8.	Ramaswamy B, Shapiro CL. Bisphosphonates in the prevention and treatment of bone metastases[J]. Oncology (Huntingt), 2003, 17(9): 1261-1270.
9.	金高娃, 那仁图雅. 唑来膦酸和帕米膦酸二钠治疗肿瘤骨转移性骨痛的比较研究[J]. 内蒙古医学杂志, 2010, 42(2): 219-220.

1. 　Zeimer H, Firkin F, Grill V, et al. A ssessm en t of cellular expression of parathyroid hormone-related protein mRNA and protein in multiple myeloma[J]. J Pathol, 2000, 192(3): 336-341.
2. 　Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials[J]. J Clin Oncol, 2001, 19(2): 558-567.
3. 　Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases inpatients with breast cancer or osteolytic lesions of multiple myeloma: a phaseⅢ, double-blind, comparative trial [J].Cancer J, 2001, 7(5): 377-387.
4. 　Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial[J]. Cancer, 2003, 98(8): 1735-1744.
5. 　罗利琼, 张丽娟, 冯刚. 唑来膦酸治疗多发性骨髓瘤骨痛的疗效[J]. 实用医学杂志, 2010, 26(17): 3223-3224.
6. 　Santini D, Fratto ME, Vincenzi B, et al. Bisphosphonate effects in cancer and inflammatory diseases: in vitro and in vivo modulation of cytokine activities[J]. BioDrugs, 2004, 18(4): 269-278.
7. 　Heidenreich A, Ohlmann CH. Ibandronate its pharmacology and clinical efficacy in the management of tumor-induced hypercalcemia and metastatic bone disease[J]. Expert Rev Anticancer Ther, 2004, 4(6): 991-1005.
8. 　Ramaswamy B, Shapiro CL. Bisphosphonates in the prevention and treatment of bone metastases[J]. Oncology (Huntingt), 2003, 17(9): 1261-1270.
9. 　金高娃, 那仁图雅. 唑来膦酸和帕米膦酸二钠治疗肿瘤骨转移性骨痛的比较研究[J]. 内蒙古医学杂志, 2010, 42(2): 219-220.

West China Medical Journal

唑来膦酸在一例多发性骨髓瘤患者中的应用

Abstract Full text Figures/Tables Video References Cited by

Format

Content